Morning Overview on MSN
The first-ever drug aimed at pancreatic cancer’s ‘untreatable’ KRAS mutation just cleared the FDA’s safe-to-proceed letter — full phase 1/2 results drop at ASCO this ...
For more than four decades, oncologists have known that a single protein drives nearly all pancreatic cancers, and for just ...
Morning Overview on MSN
The government just greenlit a daraxonrasib expanded-access program for pancreatic-cancer patients with the KRAS G12C mutation — opening the new targe…
For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...
A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression ...
A new once-daily pill almost doubled the survival time for patients battling an aggressive and advanced form of pancreatic ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an ...
A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...
D3 Bio Inc., a global clinical-stage biotechnology company dedicated to developing innovative oncology therapeutics, announced first-line (1L) clinical data of elisrasib monotherapy and elisrasib in ...
Bottom line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...
A mutation in the KRAS gene may affect your treatment options and outlook with colorectal cancer. Researchers are looking into new treatments that can target KRAS mutations. Colorectal cancer occurs ...
A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...
Spatial molecular profiling of a resected pancreatic adenocarcinoma. Fluorescently-labeled probes bind to RNA targets to identify the location of different cell types within a tumor sample. A common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results